Sample Page
Author:
Zhongshan Kangfang Biological Medicine Co., LTD
Posted Date:
April 28, 2026
Ivonescimab Receives Major Recommendations Across Multiple Therapies in the 2026 CSCO NSCLC Guideline
Zhongshan Kangfang Biological Medicine Co., LTD
April 28, 2026
Cadonilimab Combination Demonstrates Promising Survival Benefit in Locally Advanced Pancreatic Cancer: Phase II COMPASSION-26 Data Presented at AACR 2026
Zhongshan Kangfang Biological Medicine Co., LTD
April 20, 2026
Akeso Presents Updated Data on Cadonilimab Combination Therapy in PD-(L)1 Inhibitor-Resistant Advanced NSCLC at ELCC 2026
Zhongshan Kangfang Biological Medicine Co., LTD
April 7, 2026
Ivonescimab Shows Quality of Life Benefits in Chemotherapy-Free First-Line NSCLC: Health-Related Quality of Life Data from the HARMONi-2 Study Presented at ELCC 2026
Zhongshan Kangfang Biological Medicine Co., LTD
March 31, 2026
Akeso Reports Full-Year 2025 Financial Results
Zhongshan Kangfang Biological Medicine Co., LTD
March 27, 2026
Akeso Advances “IO 2.0 + ADC 2.0” Strategy with Phase II Initiation of Novel ADCs Combined with Ivonescimab and Cadonilimab
Zhongshan Kangfang Biological Medicine Co., LTD
March 24, 2026
Akeso Announces Global First-in-Class Trispecific Antibody AK150 Enters Clinical Trials: A Triple-Target Approach to Overcome Immunotherapy Resistance
Zhongshan Kangfang Biological Medicine Co., LTD
March 15, 2026
Cadonilimab Achieves 100% 24-Month OS in Complete Responders in R/M Cervical Cancer Based on Long-Term Phase II Results
Zhongshan Kangfang Biological Medicine Co., LTD
March 4, 2026
Akeso and INOVIO Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)
Zhongshan Kangfang Biological Medicine Co., LTD
March 4, 2026
Akeso’s IL-4Rα/ST2 Bispecific Antibody Cleared for Seven Phase II Studies in China Spanning Respiratory and Autoimmune Indications
Zhongshan Kangfang Biological Medicine Co., LTD
February 11, 2026
1
2
Next
